SAN DIEGO, Nov. 12, 2013 /PRNewswire-iReach/ -- SignalRX Pharmaceuticals Inc., focused on developing more effective oncology drugs through molecular design imparting multiple target inhibition, today announced the issuance of U.S. Patent No. 8,557,807 entitled "Thienopyranones as kinase inhibitors" by the U.S. Patent and Trademark Office claiming composition of matter for a broad generic molecular scaffold (TP) of compounds that possess novel kinase inhibition profiles aimed at imparting maximum anticancer efficacy. This U.S. patent grants coverage of the TP scaffold compounds into the year 2029 and is complemented by additional U.S. applications as well as by corresponding patent applications pending in other major markets throughout the world.
The compounds covered in the patent inhibit PI3 kinase and several other key cancer target kinases such as mTORC1, mTORC2, DNA-PK, PLK1 and PIM1. Further mechanisms of action include induction of oxidative stress and demonstrated anti-cancer stem cell activity. Furthermore, certain of these compounds can be molecularly manipulated to maintain their PI3 kinase inhibitory activity while simultaneously also inhibiting certain other key cancer targets providing dual inhibition from a single molecule, in line with the CRIMP (Control Resulting from Inhibition of Multiple Pathways) platform which is focused on the development of more effective cancer treatments. Additionally, other diseases besides cancer such as, age-related macular degeneration and autoimmune diseases along with various inflammatory diseases all potentially can be treated by the kinase inhibition properties of these compounds.
"This patent is a key member of our growing intellectual property portfolio as it provides protection for the cutting edge efforts to deliberately design molecules having multiple mechanisms of action to overcome the devastating ability of cancer cells to shrug
|SOURCE SignalRx Pharmaceuticals Inc.|
Copyright©2012 PR Newswire.
All rights reserved